Retour

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

News Conference Calls/ Webcasts

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

GlobeNewswire Inc. • 09/05/2024 à 20:51:00
Lumos Pharma, Inc. Common Stock
Address: 4200 MARATHON BLVD.
Postal Code: 78756
City: AUSTIN
State: TX
Phone Number: 512-215-2630
Website: https://www.lumos-pharma.com
Status: Active
Company Info

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.

List Date2011-11-11
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001126234
Composite figiBBG001CDB921
Share Class figiBBG001TWRSN9
Market Cap20,615,880 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees33
Share Class Shares Outstanding8119999
Weighted Shares Outstanding8116488
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
2.545
2.54
2.255
2.54
2.855
Variance
0.08%
12.64%
-11.57%
-10.66%
-5.4%
Open
2.543
2.255
2.55
2.843
3.018
Highest
2.595
2.634
2.629
2.844
3.018
Lowest
2.58
2.63
2.626
2.84
2.95
History
PeriodVarhighestlowest
1 week
-15.67%
3.018
2.58
1 month
-1.74%
2.76
2.58
3 month
-35.86%
3.968
2.58
6 month
-13.14%
3.1
2.58
1 year
-29.11%
3.725
2.58
3 year
-75.15%
10.37
2.58
5 year
-64.7%
8.99
2.58
10 year
-64.7%
8.99
2.58
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-10 2023-11-07 UNPUB
Assets 63,725,000 56,373,000 47,751,000 UNPUB
Current Assets 63,253,000 55,983,000 47,447,000 UNPUB
Current Liabilities 5,017,000 6,545,000 6,116,000 UNPUB
Equity 52,519,000 43,661,000 35,492,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 52,519,000 43,661,000 35,492,000 UNPUB
Liabilities 11,206,000 12,712,000 12,259,000 UNPUB
Liabilities And Equity 63,725,000 56,373,000 47,751,000 UNPUB
Noncurrent Assets 472,000 390,000 304,000 UNPUB
Noncurrent Liabilities 6,189,000 6,167,000 6,143,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-10 2023-11-07 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -11,969,000 -6,176,000 -2,305,000 UNPUB
Net Cash Flow, Continuing -11,969,000 -6,176,000 -2,305,000 UNPUB
Net Cash Flow From Financing Activities -309,000 -574,000 -435,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -309,000 -574,000 -435,000 UNPUB
Net Cash Flow From Investing Activities -2,463,000 1,083,000 5,950,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -2,463,000 1,083,000 5,950,000 UNPUB
Net Cash Flow From Operating Activities -9,197,000 -6,685,000 -7,820,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -9,197,000 -6,685,000 -7,820,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-10 2023-11-07 UNPUB
Comprehensive Income/Loss -7,342,000 -8,937,000 -8,293,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -7,342,000 -8,937,000 -8,293,000 UNPUB
Other Comprehensive Income/Loss -7,342,000 -8,937,000 -8,293,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent 4,000 -6,000 7,000 UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-05 2023-08-10 2023-11-07 UNPUB
Basic Earnings Per Share -1 -1 -1 UNPUB
Benefits Costs and Expenses 0 9,487,000 8,307,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 8,726,000 9,487,000 8,307,000 UNPUB
Diluted Earnings Per Share -1 -1 -1 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,346,000 -8,931,000 -8,300,000 UNPUB
Income/Loss From Continuing Operations Before Tax 691,000 -8,960,000 -8,300,000 UNPUB
Income Tax Expense/Benefit 0 -29,000 0 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,346,000 -8,931,000 -8,300,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -7,346,000 -8,931,000 -8,300,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -7,346,000 -8,931,000 -8,300,000 UNPUB
Operating Expenses 8,726,000 10,170,000 8,939,000 UNPUB
Operating Income/Loss -8,035,000 -9,643,000 -8,932,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 691,000 527,000 7,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-14 2023-03-07
Assets 93,190,000 85,453,000 79,209,000 72,292,000
Current Assets 92,645,000 84,988,000 78,832,000 72,009,000
Current Liabilities 5,242,000 4,832,000 5,483,000 6,708,000
Equity 81,817,000 74,546,000 67,707,000 59,584,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 81,817,000 74,546,000 67,707,000 59,584,000
Liabilities 11,373,000 10,907,000 11,502,000 12,708,000
Liabilities And Equity 93,190,000 85,453,000 79,209,000 72,292,000
Noncurrent Assets 545,000 465,000 377,000 283,000
Noncurrent Liabilities 6,131,000 6,075,000 6,019,000 6,000,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-14 2023-03-07
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 -38,802,000
Net Cash Flow, Continuing 0 0 0 -38,802,000
Net Cash Flow From Financing Activities -18,000 -2,000 -326,000 -821,000
Net Cash Flow From Financing Activities, Continuing -18,000 -2,000 -326,000 -821,000
Net Cash Flow From Investing Activities 8,051,000 7,247,000 5,845,000 -11,358,000
Net Cash Flow From Investing Activities, Continuing 8,051,000 7,247,000 5,845,000 -11,358,000
Net Cash Flow From Operating Activities -8,033,000 -7,245,000 -5,519,000 -26,623,000
Net Cash Flow From Operating Activities, Continuing -8,033,000 -7,245,000 -5,519,000 -26,623,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-14 2023-03-07
Comprehensive Income/Loss -7,720,000 -7,844,000 -7,251,000 -31,071,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,720,000 -7,844,000 -7,251,000 -31,071,000
Other Comprehensive Income/Loss 0 0 0 -31,071,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -9,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-11 2022-08-10 2022-11-14 2023-03-07
Basic Earnings Per Share -1 -1 -1 -4
Benefits Costs and Expenses 0 0 0 32,598,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 7,842,000 8,327,000 8,047,000 32,598,000
Diluted Earnings Per Share -1 -1 -1 -4
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,720,000 -7,844,000 -7,251,000 -31,062,000
Income/Loss From Continuing Operations Before Tax -7,720,000 -7,844,000 497,000 -31,075,000
Income Tax Expense/Benefit 0 0 0 -13,000
Interest Expense, Operating 0 0 0 UNPUB
Net Income/Loss -7,720,000 -7,844,000 -7,251,000 -31,062,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,720,000 -7,844,000 -7,251,000 -31,062,000
Net Income/Loss Available To Common Stockholders, Basic -7,720,000 -7,844,000 -7,251,000 -31,062,000
Operating Expenses 7,842,000 8,327,000 8,047,000 33,563,000
Operating Income/Loss -7,731,000 -7,924,000 -7,550,000 -32,040,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 111,000 403,000 497,000 1,523,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-06 2021-11-05 2022-03-11
Assets 120,062,000 114,269,000 106,465,000 100,312,000
Current Assets 119,601,000 113,476,000 105,754,000 99,677,000
Current Liabilities 4,984,000 6,777,000 6,053,000 5,130,000
Equity 108,972,000 101,122,000 94,124,000 88,977,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 108,972,000 101,122,000 94,124,000 88,977,000
Liabilities 11,090,000 13,147,000 12,341,000 11,335,000
Liabilities And Equity 120,062,000 114,269,000 106,465,000 100,312,000
Noncurrent Assets 461,000 793,000 711,000 635,000
Noncurrent Liabilities 6,106,000 6,370,000 6,288,000 6,205,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-06 2021-11-05 2022-03-11
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 15,422,000 -6,405,000 -7,046,000 -3,870,000
Net Cash Flow, Continuing 15,422,000 -6,405,000 -7,046,000 -3,870,000
Net Cash Flow From Financing Activities -166,000 -26,000 0 -192,000
Net Cash Flow From Financing Activities, Continuing -166,000 -26,000 0 -192,000
Net Cash Flow From Investing Activities 26,000,000 -10,000 -7,000 25,970,000
Net Cash Flow From Investing Activities, Continuing 26,000,000 -10,000 -7,000 25,970,000
Net Cash Flow From Operating Activities -10,412,000 -6,369,000 -7,039,000 -29,648,000
Net Cash Flow From Operating Activities, Continuing -10,412,000 -6,369,000 -7,039,000 -29,648,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-06 2021-11-05 2022-03-11
Comprehensive Income/Loss -8,631,000 -8,670,000 -7,488,000 -30,430,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -8,631,000 -8,670,000 -7,488,000 -30,430,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-08-06 2021-11-05 2022-03-11
Basic Earnings Per Share -1 -1 -1 -4
Benefits Costs and Expenses 8,631,000 8,680,000 7,488,000 31,296,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 8,631,000 8,680,000 7,488,000 31,296,000
Diluted Earnings Per Share -1 -1 -1 -4
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -8,631,000 -8,670,000 -7,488,000 -30,430,000
Income/Loss From Continuing Operations Before Tax -8,631,000 -8,670,000 -7,488,000 -31,066,000
Income Tax Expense/Benefit 0 0 0 -636,000
Interest Expense, Operating 37,000 0 0 UNPUB
Net Income/Loss -8,631,000 -8,670,000 -7,488,000 -30,430,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -8,631,000 -8,670,000 -7,488,000 -30,430,000
Net Income/Loss Available To Common Stockholders, Basic -8,631,000 -8,670,000 -7,488,000 -30,430,000
Operating Expenses 8,617,000 8,674,000 7,497,000 31,577,000
Operating Income/Loss -8,617,000 -8,664,000 -7,497,000 -31,347,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 10,000 0 230,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-06-02 2020-08-14 2020-11-12 2021-03-09
Assets 182,955,000 172,198,000 136,188,000 129,033,000
Current Assets 93,159,000 170,737,000 135,155,000 128,449,000
Current Liabilities 46,767,000 42,561,000 6,965,000 6,461,000
Equity 121,538,000 116,465,000 118,535,000 116,572,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 121,538,000 116,465,000 118,535,000 116,572,000
Liabilities 61,417,000 55,733,000 17,653,000 12,461,000
Liabilities And Equity 182,955,000 172,198,000 136,188,000 129,033,000
Noncurrent Assets 89,796,000 1,461,000 1,033,000 584,000
Noncurrent Liabilities 14,650,000 13,172,000 10,688,000 6,000,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-06-02 2020-08-14 2020-11-12 2021-03-09
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 67,745,000 32,878,000 93,727,000
Net Cash Flow, Continuing 0 67,745,000 32,878,000 93,727,000
Net Cash Flow From Financing Activities -80,869,000 80,859,000 -11,000 75,000
Net Cash Flow From Financing Activities, Continuing -80,869,000 80,859,000 -11,000 75,000
Net Cash Flow From Investing Activities 84,179,000 -14,000 32,496,000 116,649,000
Net Cash Flow From Investing Activities, Continuing 84,179,000 -14,000 32,496,000 116,649,000
Net Cash Flow From Operating Activities -3,310,000 -13,100,000 393,000 -22,997,000
Net Cash Flow From Operating Activities, Continuing -3,310,000 -13,100,000 393,000 -22,997,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-06-02 2020-08-14 2020-11-12 2021-03-09
Comprehensive Income/Loss 340,000 -5,353,000 1,765,000 -5,663,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent 340,000 -5,353,000 1,765,000 -5,663,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-06-02 2020-08-14 2020-11-12 2021-03-09
Basic Earnings Per Share UNPUB UNPUB 0 UNPUB
Benefits Costs and Expenses 5,144,000 6,812,000 741,000 19,804,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 5,144,000 6,812,000 741,000 19,804,000
Diluted Earnings Per Share UNPUB UNPUB 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax 340,000 -5,353,000 1,765,000 -5,663,000
Income/Loss From Continuing Operations Before Tax -5,123,000 -6,779,000 -667,000 -19,636,000
Income Tax Expense/Benefit -5,463,000 -1,400,000 -2,432,000 -13,973,000
Interest Expense, Operating 48,000 0 0 UNPUB
Net Income/Loss 340,000 -5,353,000 1,765,000 -5,663,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent 340,000 -5,353,000 1,765,000 -5,663,000
Net Income/Loss Available To Common Stockholders, Basic -311,000 -5,353,000 1,765,000 -6,314,000
Operating Expenses 5,236,000 6,910,000 7,231,000 26,471,000
Operating Income/Loss -5,215,000 -6,877,000 -7,157,000 -26,303,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 651,000
Preferred Stock Dividends And Other Adjustments 0 0 0 651,000
Revenues 21,000 33,000 74,000 168,000
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★
11:30
United States
5.165
★
11:30
United States
5.250
★
11:30
United States
★
11:30
United States
★
10:30
United States
★★
09:00
United States
★★
09:00
United States
★★
08:45
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
News Stream
Stocks Earnings Releases and Operating Results
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial
GlobeNewswire Inc. • 5d ago
News Conference Calls/ Webcasts
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Lumos Pharma’s management will present and host virtual one-on-one meetings with the investment community on Wednesday, February 14 during the event.
GlobeNewswire Inc. • 3mo ago
Management Directors and Officers
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), effective January 1, 2024. In this role, Dr. Pitukcheewanont will provide his leadership in Lumos Pharma's efforts to hone its clinical and regulatory strategy, and he will continue to oversee medical affairs as the Company prepares to initiate its pivotal Phase 3 trial evaluating the efficacy of oral LUM-201 in treating moderate pediatric growth hormone deficiency (PGHD).
GlobeNewswire Inc. • 4mo ago
Calendar Calendar of Events
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Webinar to be Held December 6, 2023 at 1:30pm EST Webinar to be Held December 6, 2023 at 1:30pm EST
GlobeNewswire Inc. • 6mo ago
Calendar Calendar of Events
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference.
GlobeNewswire Inc. • 6mo ago
News News
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
Lumos (LUMO) delivered earnings and revenue surprises of 5.45% and 96.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research • 6mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT